Goldline tablets, manufactured by the Indian pharmaceutical company Ranbaxy Laboratories Ltd., belong to the group of drugs with a central mechanism of action for the treatment of obesity. Its main active ingredient Sibutramine produces primary and secondary amines. As a result of biochemical reactions, the need for food decreases, a feeling of fullness quickly appears, which leads to weight loss.
A positive side effect of using Goldline is a decrease in the concentration of total cholesterol, lipoproteins, triglycerides and uric acid. The drug is available in the form of white or yellow capsules with a blue cap.
Composition:
The main active ingredient is Sibutramine;
Excipients – microcellulose, lactose, magnesium stearate, silicon dioxide;
Substances that make up the capsule shell – gelatin, magnesium lauryl sulfate, titanium dioxide, dyes.
Indications for use
Treatment of alimentary obesity with BMI over 30 kg/m2;
Relief of risk factors associated with excess weight in non-insulin dependent diabetes mellitus, dyslipidemia.
The drug Goldline is used exclusively on the recommendation and under the supervision of the attending physician, as an element of complex therapy. Obesity therapy includes dietary changes and optimal physical activity. The use of the drug makes it possible to rebuild eating habits and lifestyle. A persistent change in habits will help maintain the results achieved during therapy. Otherwise, after discontinuation of the drug, a repeated increase in body weight will occur.
dosage
The drug is taken in the morning, once on an empty stomach or during breakfast. Capsules are not chewed, washed down with plenty of water.
Доза:
10 mg – initial dose;
5 mg – initial dose with poor tolerance;
15 mg – dose taken after a month, with insufficient weight loss (less than 5%).
The total maximum duration of treatment is 2 years or less. With an abrupt increase and decrease in weight (within 3 kg for 3 months), treatment with Goldline is considered ineffective and is discontinued.
In case of an overdose of the drug, symptoms such as increased blood pressure, increased heart rate, and headache may appear. The drug is stopped, gastric lavage is performed, sorbents are used to reduce the concentration of Sibutramine in the stomach.
Противопоказания
Obesity caused by organic causes (hypothyroidism), or psychological changes (bulimia, anorexia);
Tics, mental illness;
The use of drugs acting on the central nervous system (neuroleptics, antidepressants);
Diseases of the cardiovascular system (ischemic disease, arrhythmias, tachycardia, condition after a stroke);
kidney or liver failure;
Thyrotoxicosis;
Persistent increase in blood pressure over 145/90 mm Hg;
Pregnancy;
Lactation;
Dependence on alcohol and drugs;
Hyperplasia of the prostate;
Children’s, teenage and advanced age;
Glaucoma.
With caution, Goldline is used for arrhythmia, mental retardation, motor and verbal tics, arterial hypertension, cholelithiasis, mild and moderate impairment of the liver and kidneys. During treatment with this drug, women of childbearing age should use contraceptives.
Side effects
These manifestations occur in most cases at the beginning of treatment, during the first month. Further, they become less pronounced, appear less frequently. All side effects are reversible, with the abolition of the drug disappear completely.
Symptoms of side effects:
Digestive organs – constipation, nausea, dryness of the oral mucosa, change in taste, loss of appetite;
CNS – headache, dizziness, insomnia, parasthesia;
Heart and blood vessels – tachycardia, increased blood pressure, increased heart rate;
Skin – itching, increased sweating, hemorrhages under the skin;
swelling;
Flu-like syndrome;
Irritability;
Anxiety;
Pain in the back and abdomen.
Treatment with Goldline requires careful monitoring of blood pressure and heart rate. At the beginning of treatment, these indicators are monitored at least once every 2 weeks, after 2 months – once a month. If there is a history of arterial hypertension, blood pressure levels are monitored as often as possible. Double excess of 145/90 mm Hg. indicates the termination of treatment.